Rose Geoffrey Beran sold $18K of LUNG
Rose Geoffrey Beran (Chief Commercial Officer) sold 7,879 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
The sale is routine and unlikely to affect price materially.
Market read
Minor insider sale with limited trading relevance.
What to watch
Potential upcoming clinical data releases or FDA decisions could outweigh the impact of this small sale.
Background
SEC Form 4 disclosures provide the first public record of insider trades.
Ticker impact
Chief Commercial Officer sold 7,879 shares of Pulmonx (LUNG) for $17,806.54 in a Form 4 filing.
Minimal downward pressure, likely within normal trading noise.
Sale represents less than 2% of the insider's post‑transaction holdings and the amount is small ($18K).
Market effects
None; Pulmonx operates in a niche medical device segment with limited peer impact.
No regional effect; the transaction is company‑specific.
Low; the filing does not affect broader market sentiment.
Counterpoint
If the sale signals insider concern, a short‑term dip could be exploited.
Key entities
- CompanyPulmonx Corp
Medical device company listed on NASDAQ under LUNG.
- InsiderRose Geoffrey Beran
Chief Commercial Officer of Pulmonx.